title: Clinical development of rivaroxaban: emerging new clinical evidences?
abstract: Rivaroxaban has proven efficacious in a variety of conditions. In fact, rivaroxaban has been approved for the prevention of venous thromboembolism after elective hip or knee replacement surgery, for the prevention and treatment of deep vein thrombosis and pulmonary embolism, for the prevention of stroke in patients with nonvalvular atrial fibrillation and for the prevention of atherothrombotic events after acute coronary syndrome with elevated cardiac biomarkers. However, clinical development of rivaroxaban is ongoing. Considering published and on-going randomized clinical trials, noninterventional studies and registries, over 275,000 patients are being analyzed. The aim of this review was to update the clinical development of rivaroxaban, including completed and ongoing studies not only randomized clinical trials, but also clinical practice studies.
authors.affiliation: Arrhythmia Section, Institut del Torax, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
authors.forename: Luís
authors.initials: L
authors.lastname: Mont
authors.affiliation: Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, Instituto de Investigación Biosanitaria Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Marín
authors.affiliation: Internal Medicine Service, Hospital Universitario Dr. Josep Trueta, Girona, Spain.
authors.forename: Fernando García-Bragado
authors.initials: FG
authors.lastname: Dalmau
authors.affiliation: Cardiovascular Critical Unit, Department of Cardiology. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: Marianela Sánchez
authors.initials: MS
authors.lastname: Martínez
authors.affiliation: Neurology Department and Stroke Unit, Complejo Hospitalario de Navarra, Pamplona, Spain.
authors.forename: Jaime Gallego
authors.initials: JG
authors.lastname: Cullere
mesh_terms: D001281:Atrial Fibrillation / Q000150:complications; D065427:Factor Xa Inhibitors / Q000493:pharmacokinetics; D006801:Humans; D000069552:Rivaroxaban / Q000493:pharmacokinetics*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D065427:Factor Xa Inhibitors; D000069552:Rivaroxaban
keywords: acute coronary syndrome; deep vein thrombosis; direct oral anticoagulant; new oral anticoagulant; nonvalvular atrial fibrillation; pulmonary embolism; rivaroxaban; venous thromboembolism